[Federal Register Volume 84, Number 47 (Monday, March 11, 2019)]
[Notices]
[Pages 8731-8732]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-04408]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Advisory Committee on Blood and Tissue Safety and
Availability
AGENCY: Department of Health and Human Services, Office of the
Secretary, Office of the Assistant Secretary for Health.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S.
Department of Health and Human Services is hereby giving notice that
the Advisory Committee on Blood and Tissue Safety and Availability
(ACBTSA) will hold a meeting. The meeting will be open to the public.
DATES: The meeting will take place Monday, April 15, 2019, from 8:00
a.m.-4:30 p.m. and Tuesday, April 16, 2019, from 8:30 a.m.-4:00 p.m.
ADDRESSES: U.S. Department of Health & Human Services, Hubert H.
Humphrey Building, (Conference Room 800), 200 Independence Ave. SW,
Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT: Mr. James Berger, Designated Federal
Officer for the ACBTSA, Senior Advisor for Blood and Tissue Policy,
Office of the Assistant Secretary for Health, Department of Health and
Human Services, Mary E. Switzer Building, 330 C Street SW, Suite L100,
Washington, DC 20024. Phone: (202) 795-7697; Fax: (202) 691-2102;
Email: [email protected].
SUPPLEMENTARY INFORMATION: The ACBTSA provides advice to the Secretary
through the Assistant Secretary for Health. The Committee advises on a
range of policy issues to include: (1) Identification of public health
issues through surveillance of blood and tissue safety issues with
national survey and data tools; (2) identification of public health
issues that affect availability of blood, blood products, and tissues;
(3) broad public health, ethical, and legal issues related to the
safety of blood, blood products, and tissues; (4) the impact of various
economic factors (e.g., product cost and supply) on safety and
availability of blood, blood products, and tissues; (5) risk
communications related to blood transfusion and tissue transplantation;
and (6) identification of infectious disease transmission issues for
blood, organs, blood stem cells and tissues. The Committee has met
regularly since its establishment in 1997.
[[Page 8732]]
In 2013, updates were made to the original 1994 Public Health
Service Guidelines on Reducing HIV, HBV, and HCV through Organ
Transplantation (``PHS Guidelines''). Public and private-sector
stakeholders in organ transplantation are now seeking to explore
potential important updates to the PHS Guidelines in order to maintain
accordance with current health sector circumstances.
The Committee will meet on April 15-16, 2019 to receive
presentations from various public and private sector stakeholders and
to listen to public comments regarding the PHS Guidelines. The
Committee will explore important questions to consider as the PHS
Guidelines are examined for any such necessary updates. Finally, the
Committee will discuss and develop appropriate recommendations for HHS
consideration. Additional topics that are pertinent to the mission of
the Committee may be added to the agenda.
The public will have an opportunity to present their views to the
Committee during public comment sessions scheduled for the second day
of the meeting. Comments will be limited to five minutes per speaker
and must be pertinent to the discussion. Pre-registration is required
for participation in the public comment session. Any member of the
public who would like to participate in this session is required to
submit their name, email, and comment summary prior to close of
business on April 8, 2019. If it is not possible to provide 30 copies
of the material to be distributed at the meeting, then individuals are
requested to provide a minimum of one (1) copy of the document(s) to be
distributed prior to the close of business on April 8, 2019. It is also
requested that any member of the public who wishes to provide comments
to the Committee utilizing electronic data projection submit the
necessary material to the Designated Federal Officer prior to the close
of business on April 8, 2019.
Dated: February 26, 2019.
James J. Berger,
Senior Advisor for Blood and Tissue Policy.
[FR Doc. 2019-04408 Filed 3-8-19; 8:45 am]
BILLING CODE 4150-41-P